VivoSim Labs Expands Human Disease Modeling Services
The San Diego-based firm is introducing new efficacy testing for liver and intestinal conditions.
Updated on Oct. 21, 2026 in Diseases — General
Live Poll
Do you believe patient-derived tissue models will make new drugs safer and more effective?
VivoSim Labs has expanded its NAMkind platform to include new human disease model efficacy testing services. These models utilize patient-derived cells to help developers test drug candidates before moving to clinical trials.
Why it matters
Drug developers often struggle with clinical trial failures, with lack of efficacy being the most common reason. These human tissue models offer a way to assess potential treatments before testing in humans.
The liver model conducts repeated dosing over 14 or 21 days to measure fibrosis, while the intestinal platform uses 12 available donor organoids. These models utilize patient-derived cells from individuals with conditions like MASH, Crohn's disease, or ulcerative colitis.
The players
VivoSim Labs
This San Diego-based biotechnology company specializes in developing human tissue models for drug efficacy and toxicology testing.
The details
The liver model incorporates healthy human liver cells alongside stellate, Kupffer, and endothelial cells from patients. The intestinal platform assesses barrier integrity, inflammation, and fibrosis using organoids in a single well.
Timeline
May 2025: VivoSim Labs received a Poster of Distinction award at Digestive Disease Week.
October 21, 2026: VivoSim Labs announced the expansion of its service platform.
The Big Picture
The launch of these models reflects an industry-wide transition toward human-centric testing methods aligned with the FDA Modernization Act 2.0. This evolution aims to reduce reliance on legacy models that often fail to predict human clinical outcomes.
These testing models may accelerate the development of safer, more effective treatments for chronic conditions like ulcerative colitis and liver disease. By reducing failure rates in clinical trials, patients could gain faster access to innovative therapies.
The takeaway
Reliable disease models are critical for identifying ineffective compounds early in the drug development pipeline. Developers can use these human-derived systems to better predict how patients might respond to new medical interventions.
Further reading
For more on the state of medical research, visit our Diseases — General section.
Live Poll
Do you believe patient-derived tissue models will make new drugs safer and more effective?
